Research review
Does milk thistle help with fatty liver, cirrhosis or hepatitis? What the research does and doesn't show
In two of the largest, longest human trials of milk thistle, a 2-year trial in alcoholic cirrhosis and an NIH-funded trial in chronic hepatitis C at higher-than-typical doses, silymarin showed no benefit over placebo. Results are more positive, though still unconfirmed, specifically in fatty liver disease (NAFLD).
The evidence doesn't support milk thistle as a treatment for cirrhosis or hepatitis C — two of the field's largest and longest human trials, a 2-year cirrhosis trial and an NIH-funded hepatitis C trial, found no benefit over placebo, even at doses well above what's typically sold. Results look more positive, though still unconfirmed, specifically in fatty liver disease, which milk thistle benefits: what the research does and doesn't show covers in depth.
What the evidence doesn't support
It doesn't support milk thistle as a treatment for cirrhosis, hepatitis C, or any diagnosed liver disease, and it doesn't support taking it as a substitute for antiviral treatment, a transplant evaluation, or any doctor-directed care for a liver condition. It doesn't support "will milk thistle lower liver enzymes" as a universal yes — the answer depends heavily on which disease and which trial. None of the research below describes a specific brand's dose or product, and nothing here is a claim about any product.
What the trials found
The most sobering data comes from two of the largest, best-controlled trials in the entire milk thistle literature. A 1998 trial in Journal of Hepatology enrolled 200 people with biopsy-confirmed alcoholic cirrhosis, gave half 450 mg/day of silymarin and half placebo, and followed them for up to two years with survival as the primary outcome. Twenty-nine people died during the trial — 15 on silymarin, 14 on placebo — and survival didn't differ meaningfully between groups regardless of sex, continued drinking, or how advanced the liver disease was. The authors' conclusion was direct: silymarin had no effect on survival or the disease's clinical course.
A 2012 NIH-funded trial, published in JAMA, tested silymarin in 154 people with chronic hepatitis C who hadn't responded to interferon-based treatment — a population where liver inflammation is ongoing and measurable by blood test. This trial used doses well above what's typically sold: 420 mg/day or 700 mg/day of silymarin (as three-times-daily dosing, working out to 1,260 or 2,100 mg/day total), against placebo, for 24 weeks. Only 2 people in each of the three groups reached the study's threshold for improvement, and there was no significant difference between silymarin and placebo in liver enzyme decline, hepatitis C virus levels, or quality of life. Silymarin was as well tolerated as placebo, but it didn't outperform it.
Set against those two null results, the fatty liver (NAFLD/NASH) research is more encouraging: a 2024 pooled analysis of 26 trials in that specific population found improvements in liver enzymes, lipid markers and, in a subset with biopsy data, liver histology — though the authors still call for more confirmation, and a separate, lower-quality pooled analysis of general liver disease trials found only a clinically negligible enzyme change. Both are covered in full, with their doses and populations, on the benefits page linked above; this page focuses on the disease-specific trials that page doesn't cover.
| Trial | Population | Dose | Result |
|---|---|---|---|
| Parés 1998 (n=200) | Alcoholic cirrhosis | 450 mg/day, 2 years | No effect on survival or disease course |
| Fried 2012 / SyNCH, NIH-funded (n=154) | Chronic hepatitis C, prior interferon non-response | 1,260 or 2,100 mg/day, 24 weeks | No significant difference vs. placebo on ALT or viral load |
Questions people ask
Will milk thistle help a fatty liver?
The fatty liver-specific research is more positive than the cirrhosis and hepatitis trials above, but it's still not confirmed — see milk thistle benefits: what the research does and doesn't show for the two pooled analyses and their limits.
Does milk thistle help with cirrhosis?
The best evidence says no. A 2-year, 200-person placebo-controlled trial in alcoholic cirrhosis found no effect on survival or disease progression.
Which milk thistle is best for fatty liver?
That's a product-quality question, not a health-outcome one — no research compares specific brands. How to choose a good milk thistle supplement covers the standardization and label factors that matter regardless of the condition you're researching.
Can milk thistle cause elevated liver enzymes, liver pain, or make liver disease worse?
A 2019 safety review found no major toxicity signal for silymarin and described it as generally well tolerated, including in the high-dose hepatitis C trial above, where side effects matched placebo. See milk thistle side effects for the full breakdown.
Does milk thistle help dogs' liver disease, or kidney stones and kidney disease?
This page covers human evidence only. Dosing and safety for a dog or cat with liver disease, and any use for kidney stones or kidney disease, are questions for a veterinarian or physician rather than this research review — dosing that works in the human trials above hasn't been tested for those uses.
When to talk to a doctor
Anyone with diagnosed cirrhosis, hepatitis or another liver condition should be under a doctor's care, and shouldn't start, stop or substitute milk thistle for a prescribed treatment without medical guidance — the trials above were run alongside standard care, not instead of it. If you take any prescription medication, ask a doctor before adding milk thistle; see milk thistle and medications: what to check.
Related reading: milk thistle benefits: what the research does and doesn't show, does milk thistle detox or cleanse the liver, and who should not take milk thistle.
Sources
- Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial A 2-year, placebo-controlled trial in 200 people with alcoholic cirrhosis found 450 mg/day of silymarin had no effect on survival or the clinical course of the disease compared with placebo.
- Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial An NIH-funded trial in 154 people with chronic hepatitis C found that even higher-than-typical doses of silymarin (up to 2,100 mg/day) did not significantly reduce liver enzymes or hepatitis C viral levels more than placebo over 24 weeks.
- Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review A 2019 safety review found silymarin generally well tolerated in humans, even at high doses for 24 weeks, with gastrointestinal upset as the main limiting side effect.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.